The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
This initiative underscores a steadfast commitment of ONGC to sustainable development and enhanced public health services
Subscribe To Our Newsletter & Stay Updated
